Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer treatment known as Bispecific T-Cell Engager (BiTE) therapies on Feb. 11, 2025 ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...